Company Overview
| Stock Name | 3Sbio |
|---|---|
| Stock Code | 01530 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事生物制藥產品的開發、生產、市場推廣及銷售。 |
| Listing Date | 2015-06-11 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國遼寧省沈陽市經濟技術開發區十號路1甲3號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.3sbio.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 9.10 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 5.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 2,206,204,000 |
Stock Connect Inclusion
| HK Market Cap | --- |
|---|---|
| Analysis Result | Already included in Stock Connect (both, shenzhen, shanghai) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 9.35 |
|---|---|
| First Day Open | HK$ 9.32 |
| First Day Change | 2.75% |
| First Day Volume | 233134000.0 |
| First Day Turnover | 2222160000.0 |
Use of Proceeds
| Use of Proceeds | 1、約45%，或約1,876.5百萬港元，將用于通過選擇性收購擴大我們重點治療領域的藥物產品組合； 2、約15%，或約625.5百萬港元，將用于透過聘額外銷售人員等方式加強我們產品的銷售及營銷； 3、約15%，或約625.5百萬港元，將用于為資本開支項目融資，以透過興建新生產線提高我們的產能； 4、約15%，或約625.5百萬港元，將用于為研發項目（包括內部研發項目及外部合作項目）融資； 5、約10%，或約417.0百萬港元，將用于補充我們的營運資金及作一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (4)
Joint Bookrunners (5)
Joint Lead Managers (5)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | BlackRock Funds | 309,986,950 HKD | — | 1.41% | — | 6 months | 2015-12-11 |
| 2 | GIC Private Limited | 232,514,100 HKD | — | 1.05% | — | 6 months | 2015-12-11 |
| 3 | Lilly Asia Ventures Fund III, L.P. | 232,514,100 HKD | — | 1.05% | — | 6 months | 2015-12-11 |
| 4 | 工银瑞信资产管理(国际)有限公司 | 77,500,150 HKD | — | 0.35% | — | 6 months | 2015-12-11 |
| 5 | 新华资产管理(香港)有限公司 | 155,009,400 HKD | — | 0.70% | — | 6 months | 2015-12-11 |
| 6 | 中国人寿富兰克林资产管理有限公司 | 155,009,400 HKD | — | 0.70% | — | 6 months | 2015-12-11 |
Directors & Management
| Chairman | 婁競 |
|---|---|
| Company Secretary | 黎少娟 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 婁競及關連人士(21.62%);貝萊德(8.92%) |
|---|
